The 90 patients in this trial were randomised into two groups – half received a single high-dose of stereotactic ablative radiotherapy or SABR, and the other had an equivalent dose of SABR but accumulated over four visits. When followed up one year later, there was a little difference in side effects and outcomes. The results indicate that SABR can be a safe and effective treatment for patients whose cancer has spread to their lungs, even when it’s delivered in a single session. In addition to clinical benefits, SABR has practical benefits for patients, such as fewer trips to a clinic, less time off work and lower treatment costs.
Results from this trial have been published in The International Journal of Radiation Oncology, Biology, Physics [Link] and The Journal of Clinical Oncology [Link]
Australasian Lung Cancer Trials Group (ALTG)
A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
The journey to becoming the 200th participant for the
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292